On March 3, 2023, Nuclera unveiled their new Global headquarters, One Vision Park in Impington, Cambridge, UK, about a year following the company’s successful Series B raise. The event, marking a new chapter in its history and creating a new space to drive the future growth. The building was inaugurated by The Rt Hon Lucy Frazer KC MP, who commended the company's commitment to improving human health and expediting the drug discovery process.
The opening ceremony was attended by a range of guests, including investors, customers and strategic partners. The building has been designed to accommodate the company's growing workforce and provides an open, modern workspace that fosters collaboration and creativity.
Speaking at the ceremony, the Rt Hon Lucy Frazer praised the company for its contribution to the local economy and highlighted the importance of investing in sustainable infrastructure to drive economic growth. She said, "This new office building is a testament to the company's commitment to the region and its vision for the future. I am delighted to be a part of this special occasion and to see the positive impact it will have on the local community."
Nuclera’s CEO, Michael Chen expressed his enthusiasm for the new building, which he described as a "significant milestone" for the company. He added, "This new headquarters represents a new era for our company, and we are proud to be making this investment in the region. We look forward to continuing to work closely with our customers and partners to drive innovation and growth."
The new headquarters will serve as a hub for the company's global operations and will house key departments such as research and development, sales and marketing, and customer service. The new space consolidates various separate office buildings into one state of the art 30,000 sq ft facility.
In conclusion, the opening of this new corporate headquarters marks an important milestone for the company and the region and will help us solidify the launch of eProtein DiscoveryTM in 2023. Chen says, “We are excited to enable drug discovery researchers with a solution for rapid protein prototyping on their benchtop”, he added, “and getting into this new state-of-the-art space will allow us to gain operational efficiencies, increase collaboration and get our product into the market in late 2023.”
